Advertisement
YOU ARE HERE: LAT HomeCollectionsNexell Therapeutics Inc
IN THE NEWS

Nexell Therapeutics Inc

FEATURED ARTICLES
BUSINESS
July 28, 2000
The Irvine developer of cell therapies for cancer and other diseases reported a loss of $8.3 million, or 53 cents a share, for the second quarter, compared with a loss of nearly $9 million, or 57 cents a share, for the same period last year. Revenue climbed to $4.6 million from $1.6 million.
ARTICLES BY DATE
BUSINESS
March 29, 2002 | From Bloomberg News
Nexell Therapeutics Inc., an Irvine biotechnology company involved in cancer research, said it's considering finding a buyer for the company, or other alternatives, and that it will run out of cash by July. Its shares Thursday fell 55 cents to close at 53 cents on Nasdaq. Auditors found there was "substantial doubt" about Nexell's ability to continue its operations, the company said in a statement. Company officials didn't return phone calls seeking comment.
Advertisement
BUSINESS
July 13, 2000 | Dow Jones
Nexell Therapeutics Inc. said Wednesday that William A. Albright Jr. has been named president and chief operating officer of the Irvine medical company. Albright replaces L. William McIntosh, who will leave the management team but continue to advise the company as a consultant and a director. Albright had been Nexell's senior vice president and chief financial officer. The company develops cell therapies and diagnostics for cancer, autoimmune, metabolic and genetic diseases.
BUSINESS
November 29, 2001 | Times Staff and Wire Reports
Nexell Therapeutics Inc. shares more than tripled Wednesday after the Irvine drug maker said it will have seven years of exclusive U.S. marketing rights for an experimental drug to treat a rare genetic blood ailment. The stock, which had lost 75% of its value this year through Tuesday, climbed $1.65 to $2.40 on Nasdaq. Nearly 8 million shares changed hands, compared with average daily volume of about 84,500 shares over the last three months.
BUSINESS
March 2, 2001 | MARC BALLON, TIMES STAFF WRITER
Nexell Therapeutics Inc., which develops cell therapies for cancers and other diseases, has elevated president and chief operating officer William A. Albright Jr. to chief executive. Albright, who helped craft the Irvine company's strategy of moving more aggressively to develop cell therapies, replaces Richard L. Dunning, who remains chairman. Albright will retain the president's title, but the position of chief operating officer will be eliminated, the company said.
BUSINESS
September 14, 1999 | (Dow Jones)
Irvine-based Nexell Therapeutics Inc. said Monday it received a $535,000 grant from the National Institutes of Health and will begin a two-year tumor-cell study.
BUSINESS
August 8, 2001
Nexell Therapeutics Inc. in Irvine said Tuesday it agreed to sell its cell-processing business to its biggest shareholder, Baxter International, for $4.3 million, plus unspecified royalties on future product sales. Nexell announced the transaction in June, but financial details were not disclosed. Nexell's remaining work force was reduced by 18 employees. The companies expect to complete the transaction by Oct. 1, Nexell said.
BUSINESS
August 15, 2001
* NetGuru Inc., a Yorba Linda information technology company, reported that its net loss for the first quarter widened to $1.2 million, or 7 cents a share, from $300,000, or 4 cents a share, a year earlier. Revenue fell 7% to $6.8 million. * Lake Forest collectibles company L.L. Knickerbocker Co. reported second-quarter profit of $180,000, contrasted with a net loss of $671,000, or 1 cent a share, for the comparable period last year. Sales declined 24% to $6.7 million.
BUSINESS
August 8, 2001
Nexell Therapeutics Inc. in Irvine said Tuesday it agreed to sell its cell-processing business to its biggest shareholder, Baxter International, for $4.3 million, plus unspecified royalties on future product sales. Nexell announced the transaction in June, but financial details were not disclosed. Nexell's remaining work force was reduced by 18 employees. The companies expect to complete the transaction by Oct. 1, Nexell said.
BUSINESS
June 13, 2001 | MARC BALLON, TIMES STAFF WRITER
Struggling Nexell Therapeutics Inc. said Tuesday that it will fire two-thirds of its work force and transfer rights to its cell-processing products to its biggest shareholder, Baxter International Inc. The Irvine developer of cell therapies to treat cancer and other diseases said Baxter's health care unit will obtain worldwide sales and marketing and distribution rights for Nexell's flagship Isolex magnetic cell-selection system, cell culture and storage containers, and other products.
BUSINESS
May 16, 2001
Collectibles company L.L. Knickerbocker Co. Inc. in Lake Forest reported a net loss $1.2 million, or 2 cents a share, for the first quarter, compared with a loss of $1.4 million, or 3 cents a share, a year earlier. Sales declined 25% to $5.4 million . . . Nexell Therapeutics Inc., an Irvine biotechnology company, posted a loss $6.1 million, or 39 cents a share, for the first quarter, compared with a net loss of $7.7 million, or 51 cents a share, for the first quarter of 2000.
BUSINESS
April 25, 2001 | Dow Jones
A federal district court judge in Delaware awarded AmCell Corp. a partial summary judgment in a patent infringement suit filed by Nexell Therapeutics Inc. in March 2000, over rival cell-separation devices. Judge Rodrick McKelvie told AmCell, a U.S.
BUSINESS
April 10, 2001 | MARC BALLON
Three Orange County companies are among the 37 California drug firms working on treatments for cancer, the nation's second-leading killer, according to a biannual survey by Pharmaceutical Research and Manufacturers of America, a Washington, D.C.-based trade organization. The local efforts: * Peregrine Pharmaceuticals Inc., a Tustin biopharmaceutical business, is working on Cotara, a drug that irradiates brain and other cancer cells.
BUSINESS
March 22, 2001 | Dow Jones
Nexell Therapeutics Inc. said Wednesday that it will seek Food and Drug Administration approval to start its own trial of engineered stem-cell grafts, based on the results of a study conducted by the National Institutes of Health. The Irvine biotechnology company said in a press release that the previous study showed "marked improvement" in the immune function of patients with chronic granulomatous disease, or CGD, despite the death of three volunteers.
BUSINESS
March 2, 2001 | MARC BALLON, TIMES STAFF WRITER
Nexell Therapeutics Inc., which develops cell therapies for cancers and other diseases, has elevated president and chief operating officer William A. Albright Jr. to chief executive. Albright, who helped craft the Irvine company's strategy of moving more aggressively to develop cell therapies, replaces Richard L. Dunning, who remains chairman. Albright will retain the president's title, but the position of chief operating officer will be eliminated, the company said.
Los Angeles Times Articles
|